NDAORALTABLET, EXTENDED RELEASE
Approved
Feb 2008
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
29
Data completeness
5/8 — Partial
PRISTIQ (desvenlafaxine succinate) by Pfizer is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. First approved in 2008.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRISTIQ (desvenlafaxine succinate) is an oral extended-release serotonin-norepinephrine reuptake inhibitor (SNRI) approved by FDA in 2008. It works by potentiating serotonin and norepinephrine in the central nervous system through inhibition of their reuptake. The exact mechanism remains incompletely understood but is consistent with SNRI class activity.
$0.007BPart D
LOE Approaching1.0 years to LOEProduct nearing patent expiration with modest Part D volume signals mid-to-late lifecycle stage with reduced team expansion opportunities.
Mechanism of Action
unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective SNRI.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (29)
A Study of LY03005 vs Pristiq
Started Jun 2018
56 enrolled
Major Depressive Disorder
Switching From SSRI to Desvenlafaxine on Cognitive Functioning
Started Apr 2018
36 enrolled
Major Depressive Disorder
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
Started Nov 2017
20 enrolled
Major Depressive Disorder
Pilot BA Study of New LY03005 vs Pristiq
Started Dec 2016
20 enrolled
Major Depression
Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQ
Started Apr 2016
700 enrolled
Major Depressive Disorder
Worked on PRISTIQ at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.